T 0233/96 (Adrenaline/MEDCO RESEARCH) du 04.05.2000
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:2000:T023396.20000504
- Date de la décision
- 4 mai 2000
- Numéro de l'affaire
- T 0233/96
- Requête en révision de
- -
- Numéro de la demande
- 89303960.2
- Classe de la CIB
- A61K 31/70
- Langue de la procédure
- Anglais
- Distribution
- Distribuées aux présidents et aux membres des chambres de recours (B)
- Téléchargement
- Décision en anglais
- Versions JO
- Aucun lien JO trouvé
- Autres décisions pour cet affaire
- -
- Résumés pour cette décision
- -
- Titre de la demande
- Use of adenosine and its derivatives in diagnosis
- Nom du demandeur
- MEDCO RESEARCH INC
- Nom de l'opposant
- -
- Chambre
- 3.3.02
- Sommaire
- -
- Dispositions juridiques pertinentes
- European Patent Convention Art 56 1973
- Mots-clés
- Novelty (yes): after limitation
Inventive step (no): claimed diagnostic application of adenosine obvious in view of its known diagnostic and therapeutic application
Second auxiliary request: reference to
no novel diagnostic application - Exergue
- If the use of a compound was known in the treatment or diagnosis of a disease of a particular group of subjects, the treatment or diagnosis of the same disease with the same compound could nevertheless represent a novel therapeutic or diagnostic application, provided that it is carried out on a new group of subjects which is distinguished from the former by its physiological or pathological status (T 0019/86, T 0893/90).
This does not apply, however if the group chosen overlaps with the group previously treated or the choice of the novel group is arbitrary which means that no functional relationship does exist between the particular physiological or pathological status of this group of subjects (here humans who are unable to exercise adequately) and the therapeutic or pharmacological effect achieved.
ORDER
For these reasons it is decided that:
The appeal is dismissed.